论文部分内容阅读
上市前,博雅生物拟收购对象公司海康生物,但此时,会影响其上市并触及重大重组及审核;上市后,博雅生物正式收购对象公司,而这次,博雅生物在交易的协议中,将价格和时间讨了个巧,轻而易举地规避了重大重组审核。博雅生物于2012年3月创业板上市,公司属于生物药品制造业,主营白蛋白、免疫球蛋白和凝血因子三大类。2012年年末,博雅生物公告称,与海康生物的控股股东温州海螺集团,
Prior to its listing, Boyaa Biological intends to acquire the target company Haikang Bio, but at this time, it will affect its listing and touch upon major reorganization and audit. After the listing, Boyaa Biologicals officially acquired the target company. At this time, The price and time for a coincidence, easily evade the major reorganization audit. Burson-Marsteller listed on the GEM in March 2012, the company belongs to the bio-pharmaceutical manufacturing industry, the main albumin, immunoglobulin and coagulation factors in three categories. At the end of 2012, Boyaa Bulletin said that with the controlling shareholder of Hai Kang Biology Conch Holdings,